TPG-backed firm to absorb Indian drugmaker’s contract development biz, go public

By Sumit Upadhyaya

  • 25 Sep 2023
Premium
Credit: 123RF.com

An Indian biopharmaceutical company that counts private equity firm TPG as an investor will absorb a local drugmaker’s contract development and manufacturing organisation (CDMO) and soft gelatin business and list on stock exchanges.  The multi-stage transaction will involve Stelis Biopharma Ltd, which secured $195 million from TPG Growth and other investors ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.